Stress signaling in the heart by AMP-activated protein kinase

Current Hypertension Reports

Volumn 8, Issue 6, 2006, Pages 446-450

  Russell III, Raymond ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; GLUCOSE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEIN KINASE; ROSIGLITAZONE; VASCULOTROPIN;

BIOGENESIS; CHOLESTEROL SYNTHESIS; DRUG BLOOD LEVEL; ENERGY METABOLISM; ENZYME ACTIVITY; GENE ACTIVATION; GENETIC TRANSCRIPTION; GLUCOSE UTILIZATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MITOCHONDRION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STRESS;

ADENOSINE; ENDOTHELIUM, VASCULAR; ENERGY METABOLISM; ENZYME ACTIVATION; FATTY ACIDS; HEART; HUMANS; MULTIENZYME COMPLEXES; MYOCARDIAL ISCHEMIA; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRIDOXINE;

EID: 33751559869     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0021-z     Document Type: Review

References (64)

1. Carling D, Clarke PR, Zammit VA, Hardie DG: Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 1989, 186:129-136.
2. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002, 277:23977-23980.
3. Horman S, Beauloye C, Vertommen D, et al.: Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2. J Biol Chem 2003, 278:41970-41976.
4. Russell RR III, Bergeron R, Shulman GI, Young LH: Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999, 277:H643-H649.
5. Russell RR III, Li J, Coven DL, et al.: AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004, 114:465-468.
6. Hayashi T, Hirshman MF, Kurth EJ, et al.: Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998, 47:1369-1373.
7. Marsin AS, Bertrand L, Rider MH, et al.: Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000, 10:1247-1255.
8. Kudo N, Barr AJ, Barr RL, et al.: High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995, 270:17513-17520.
9. Kudo N, Gillespie JG, Kung L, et al.: Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996, 1301:67-75.
10. Hardie DG, Carling D: The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem 1997, 246:259-273.
11. Winder WW, Hardie DG: AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999, 277:E1-E10.
12. Cheung PC, Salt IP, Davies SP, et al.: Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000, 346:659-669.
13. Woods A, Salt I, Scott J, et al.: The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett 1996, 397:347-351.
14. Salt I, Celler JW, Hawley SA, et al.: AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 1998, 334:177-187.
15. Holmes BF, Kurth-Kraczek EJ, Winder WW: Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999, 87:1990-1995.
16. Winder WW, Holmes BF, Rubink DS, et al.: Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000, 88:2219-2226.
17. Bergeron R, Ren JM, Cadman KS, et al.: Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 2001, 281:E1340-E1346.
18. Putman CT, Kiricsi M, Pearcey J, et al.: AMPK activation increases uncoupling protein-3 expression and mitochondrial enzyme activities in rat muscle without fibre type transitions. J Physiol 2003, 551:169-178.
19. Bamford JA, Lopaschuk GD, MacLean IM, et al.: Effects of chronic AICAR administration on the metabolic and contractile phenotypes of rat slow- and fast-twitch skeletal muscles. Can J Physiol Pharmacol 2003, 81:1072-1082.
20. Chabowski A, Momken I, Coort SL, et al.: Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol Cell Biochem 2006, 288:210-212.
21. Buhl ES, Jessen N, Pold R, et al.: Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002, 51:2199-2206.
22. Halseth AE, Ensor NJ, White TA, et al.: Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun 2002, 294:798-805.
23. Zou L, Shen M, Arad M, et al.: N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity. Circ Res 2005, 97:323-328.
24. Ahmad F, Arad M, Musi N, et al.: Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 2005, 112:3140-3148.
25. Hawley S, Boudeau J, Reid J, et al.: Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003, 2:28.
26. Shaw RJ, Kosmatka M, Bardeesy N, et al.: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004, 101:3329-3335.
27. Woods A, Dickerson K, Heath R, et al.: Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005, 2:21-33.
28. Hawley SA, Pan DA, Mustard KJ, et al.: Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005, 2:9-19.
29. Sakamoto K, Zarrinpashneh E, Budas GR, et al.: Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 2006, 290:E780-E788.
30. Davies SP, Helps NR, Cohen PT, Hardie DG: 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995, 377:421-425.
31. Coven DL, Hu X, Cong L, et al.: Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am J Physiol Endocrinol Metab 2003, 285:E629-E636.
32. Wojtaszewski JF, Nielsen P, Hansen BF, et al.: Isoform-specific and exercise intensity-dependent activation of 5′-AMP-activated protein kinase in human skeletal muscle. J Physiol 2000, 528:221-226.
33. 2. Biochem Biophys Res Commun 2001, 287:92-97.
34. Leon H, Atkinson LL, Sawicka J, et al.: Pyruvate prevents cardiac dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. Can J Physiol Pharmacol 2004, 82:409-416.
35. Barnes K, Ingram JC, Porras OH, et al.: Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 2002, 115(Pt 11):2433-2442.
36. Corton JM, Gillespie JG, Hawley SA, Hardie DG: 5-amino-imidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995, 229:558-565.
37. Zhang L, Frederich M, He H, Balschi JA: Relationship between 5-aminoimidazole-4-carboxamide-ribotide and AMP-activated protein kinase activity in the perfused mouse heart. Am J Physiol Heart Circ Physiol 2006, 290: H1235-H1243.
38. Zhou G, Myers R, Li Y, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
39. Fryer LG, Parbu-Patel A, Carling D: The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277:25226-25232.
40. Fryer LG, Hajduch E, Rencurel F, et al.: Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes 2000, 49:1978-1985.
41. Chen ZP, Mitchelhill KI, Michell BJ, et al.: AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999, 443:285-289.
42. Li J, Hu X, Selvakumar P, et al.: Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab 2004, 287:E834-841.
43. Minokoshi Y, Kim YB, Peroni OD, et al.: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
44. Steinberg GR, Rush JW, Dyck DJ: AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am J Physiol Endocrinol Metab 2003, 284:E648-E654.
45. Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
46. Shibata R, Sato K, Pimentel DR, et al.: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
47. Atkinson LL, Fischer MA, Lopaschuk GD: Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002, 277:29424-29430.
48. Baron SJ, Li J, Russell RR III, et al.: Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res 2005, 96:337-345.
49. Xing Y, Musi N, Fujii N, et al.: Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 2003, 278:28372-28377.
50. Williamson JR: Glycolytic control mechanisms. II. Kinetics of intermediate changes during the aerobic-anoxic transition in perfused rat heart. J Biol Chem 1966, 241:5026-5036.
51. Altarejos JY, Taniguchi M, Clanachan AS, Lopaschuk GD: Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase kinase. J Biol Chem 2005, 280:183-190.
52. Li J, Miller EJ, Ninomiya-Tsuji J, et al.: AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 2005, 97:872-879.
53. Tian R, Musi N, D'Agostino J, et al.: Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
54. Kantor PF, Robertson MA, Coe JY, Lopaschuk GD: Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. J Am Coll Cardiol 1999, 33:1724-1734.
55. Hickson-Bick DL, Buja ML, McMillin JB: Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 2000, 32:511-519.
56. Clark H, Carling D, Saggerson D: Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur J Biochem 2004, 271:2215-2224.
57. Gonzalez AA, Kumar R, Mulligan JD, et al.: Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity. Am J Physiol Endocrinol Metab 2004, 287: E1032-E1037.
58. Atkinson LL, Kozak R, Kelly SE, et al.: Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 2003, 284:E923-E930.
59. Dagher Z, Ruderman N, Tornheim K, Ido Y: Acute regulation of fatty acid oxidation and AMP-activated protein kinase in human umbilical vein endothelial cells. Circ Res 2001, 88:1276-1282.
60. Dagher Z, Ruderman N, Tornheim K, Ido Y: The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999, 265:112-115.
61. Ido Y, Carling D, Ruderman N: Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51:159-167.
62. Kukidome D, Nishikawa T, Sonoda K, et al.: Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006, 55:120-127.
63. Nagata D, Mogi M, Walsh K: AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003, 278:31000-31006.
64. Ouchi N, Shibata R, Walsh K: AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 2005, 96:838-846.